Article info
PDFEditors' commentary
Highlights from this issue
- Correspondence to Professor Phil Smith, University Hospital of Wales, Cardiff, UK; SmithPE{at}cardiff.ac.uk
Citation
Highlights from this issue
Publication history
- Accepted August 26, 2016
- First published September 13, 2016.
Online issue publication
September 15, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Brain abscess as an initial presentation in a patient of hereditary haemorrhagic telangiectasia caused by a novel ENG mutation
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Pulmonary arteriovenous fistula complicated by venous thromboembolism and paradoxical cerebral infarction during early pregnancy
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- SMAD4 mutations found in unselected HHT patients
- Recurrent minor strokes/TIA with a right to left shunt
- Natalizumab and PML: a risky business?
- Rare manifestations in a case of Osler-Weber-Rendu disease
- Personalised stroke evaluation and management: tailoring individualised patient care for hereditary haemorrhagic telangiectasia
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring